| Literature DB >> 33981251 |
Bernhard Grässler1, Beatrice Thielmann2, Irina Böckelmann2, Anita Hökelmann1.
Abstract
Introduction: Heart rate variability (HRV), the beat-to-beat variation of adjacent heartbeats, is an indicator of the function of the autonomic nervous system (ANS). Increased HRV reflects well-functioning of autonomic control mechanism and cardiovascular health. The aim of this systematic review is to provide a systematic overview of the effects of different physical training modalities on resting HRV and cardiovascular health and risk factors (i.e., baroreflex sensitivity, body fat, body mass, body mass index, blood pressure, heart rate recovery, VO2 max, and VO2 peak) in young and middle-aged (mean age of the studies samples up to 44 years), healthy adults.Entities:
Keywords: autonomic nervous system; cardiovascular risk factors; healthy adults; heart rate variability; physical intervention
Year: 2021 PMID: 33981251 PMCID: PMC8107721 DOI: 10.3389/fphys.2021.657274
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Description of each modified TESTEX criterion.
| 1 | Eligibility criteria specified | 1 | Information on inclusion and exclusion criteria. For HRV recording, no medication with cardiac effects |
| 0.5 | Specification of inclusion or exclusion | ||
| 0 | Not reported | ||
| 2 | Randomization specified | 1 | Yes |
| 0 | No or not reported | ||
| 3 | Allocation concealment | 1 | Yes |
| 0 | No or not reported | ||
| 4 | Groups similar at baseline | 1 | All parameters (gender, age, BMI) |
| 0.5 | Partially | ||
| 0 | No or not reported | ||
| 5 | Blinding of assessor (for at least one key outcome) | 1 | Yes |
| 0 | No or not reported | ||
| 6 | Outcome measures assessed in at least 85% of patients | 3 | Dropout of subjects <15% + report of dropout events + persistent subjects with 85% participation in sessions |
| 2 | 2 of the aforementioned | ||
| 1 | Only persistent subjects with 85% participation in sessions | ||
| 0 | Nothing or not reported | ||
| 7 | Intention-to-treat analysis | 1 | Yes |
| 0 | No | ||
| 8 | Between-group statistical comparisons reported | 2 | Reported for primary (HRV) and secondary endpoint (BMI, BP, VO2,)… |
| 1 | Reported for primary endpoint | ||
| 0 | Not reported | ||
| 9 | Point measures and measures of variability for all reported outcome measures | 1 | |
| 0.5 | Only | ||
| 0 | Not reported | ||
| 10 | Activity monitoring in control groups | 1 | Yes, with protocol |
| 0 | No or not reported | ||
| 11 | Relative exercise intensity remained constant | 1 | Increase in the process with adaptation to performance (intermediate measurement of the performance parameters) |
| 0.5 | Step-by-step concept planned from the beginning | ||
| 0 | Constant training during the monitoring period | ||
| 12 | Exercise volume and energy expenditure stated | 1 | Specification of intensity, frequency, mode and duration of the training with a minimum of: |
| 0.5 | Specification of intensity, frequency, mode, and duration of the training without VO2, 1RM, or other equivalent | ||
| 0 | Not reported |
BMI, body mass index; BP, blood pressure; HRV, heart rate variability; RM, repetition maximum; VO.
Description of each modified STARDHRV criterion.
| 1 | Title or Abstract | Identification as a study of validation | 1 | Reported |
| 0 | Not reported | |||
| 2 | Abstract | Structured summary of study objective, design, methods, results, and conclusions | 1 | Yes |
| 0.5 | Yes, but not structured | |||
| 0 | Not reported | |||
| 3 | Introduction | Scientific and practical background, including the intended use of the index device/software | 1 | Complete, including the application of the HRV method |
| 0.5 | With limitations available | |||
| 0 | Insufficient background | |||
| 4 | Study objectives and hypotheses described | 1 | Study objectives and hypothesis | |
| Study objectives without hypothesis | ||||
| 0 | Not reported | |||
| 5 | Study uses within-subject design | 1 | Reported | |
| 0 | Not reported | |||
| 6 | Intended sample size and how it was determined (e.g., G*Power 3) | 1 | Reported | |
| 0 | Not reported | |||
| 7 | Eligibility criteria including specific restrictions (medical use, gender, age, activity level or BMI) | 1 | Reported for health, medical use, gender, age, activity, and (BMI) | |
| 0.5 | Reported in some criteria <1P | |||
| 0 | Not reported | |||
| 8 | Methods | Pre-testing guidelines reported (e.g., limitations to caffeine, alcohol, physical activity, etc.) | 1 | Reported for limitations to caffeine, alcohol and physical activity |
| 0.5 | Reported in some criteria <1P | |||
| 0 | Not reported | |||
| 9 | Setup of reference standard and index device described in sufficient detail to allow replication (e.g., hardware/software such as brand, electrode configuration, etc.) | 1 | Sufficient description. A replication is possible | |
| 0.5 | Limited description. A replication is partially possible | |||
| 0 | Insufficient description. Replication is not possible | |||
| 10 | Description of environmental conditions (e.g., temperature, humidity, lights on or off, time of day) and posture | 1 | Temperature + time of day or same time of day + body position | |
| 0.5 | Reported in some criteria <1P | |||
| 0 | Not reported | |||
| 11 | A stabilization period prior to sampling was described | 1 | Yes, with information about when and how long | |
| 0.5 | Yes, with information about when or how long | |||
| 0 | Not reported | |||
| 12 | The raw sampling rate and length of collection are described | 1 | Sampling rate + length of collection | |
| 0.5 | Only length of collection | |||
| 0 | Not reported | |||
| 13 | Acknowledgment of breathing (e.g., controlled or not controlled) | 1 | Reported | |
| 0 | Not reported | |||
| 14 | Description of how estimates or comparison measures were calculated (e.g., ES, LOA, Pearson's | 1 | Reported | |
| 0 | Not reported | |||
| 15 | Reasons for missing data, along with percentage missing (e.g., equipment, persistent ectopy), and how it was handled | 1 | Reasons for missing data + percentage + handling | |
| 0.5 | Reported in some criteria <1P | |||
| 0 | Not reported | |||
| 16 | Interbeat artifact identification method (e.g., algorithm, manual inspection) | 1 | Manual inspection of artifacts | |
| 0.5 | Automatically without manual correction | |||
| 0 | Not reported | |||
| 17 | Artifact cleaning methods and percentage of beats corrected | 1 | Description Method (e.g., smoothing or decimation) and percentage | |
| 0.5 | Reported in some criteria <1P | |||
| 0 | Not reported. | |||
| 18 | Description of metrics used and software/script for HRV calculation (log transformation etc.) | 1 | Reported | |
| 0 | Not reported | |||
| 19 | Specification of frequency bands used and how they were calculated (e.g., Fast Fourier Transform or Autoregressive modeling) | 1 | Reported | |
| 0 | Not reported | |||
| 20 | Baseline demographics of participants | 1 | Reported | |
| 0 | Not reported | |||
| 21 | Results | Mean ± SD along with at least one estimates of precision (e.g., LOA, Pearson's | 1 | |
| 0.5 | Only | |||
| 0 | Not reported | |||
| 22 | Discussion | Study limitations, (e.g., sources of potential bias, confounding variables, statistical uncertainty, and generalizability) | 1 | In detail (if necessary also as extra section) |
| 0.5 | Discussed, but not in detail | |||
| 0 | Not reported | |||
| 23 | Implications for practice, including the intended use | 1 | Detailed, giving practical recommendations (e.g., clientele, how often), extra section | |
| 0.5 | Discussed, but not in detail | |||
| 0 | No statement or simple statement “We have seen differences and suggest that” | |||
| 24 | Where the full study protocol can be accessed if not fully described | 1 | Reported | |
| 0 | Not reported | |||
| 25 | Other information | Sources of funding and other support; role of funders | 1 | Information about funding and conflict of interest |
| 0.5 | Funding, conflict of Interest or acknowledgment | |||
| 0 | Not reported |
BMI, body mass index.
Figure 1PRISMA flow diagram showing identified, included, and excluded studies.
Characteristics of the studies included.
| Badrov et al., | 32 (IHG3: 12; IHG5: 11; CG: 9) | 1-lead ECG | RHR, SDNN, RMSSD, pNN50, LF (ln, ms2), HF (ln, ms2), LF nu, HF nu, TP (ln, ms2), LF/HF, SampEn, α1 | BP | 10 min (256 beats for analysis) | Isometric handgrip training | Yes |
| Bond et al., | 32 (TG: 16; CG: 16) | 2-lead ECG | RHR, HF nu | SBP, VO2 peak | 5 min | Endurance (bicycle) | Yes |
| Boutcher et al., | 32 (TG: 16; CG: 16) | Polar S810i chest belt | RHR, LF (ln, ms2), HF (ln, ms2), LF nu, HF nu | BF, BM, VO2 max | 15 min | HIIE (cycle ergometer) | yes |
| Brown et al., | 73 (NW: 27; BW: 27, CG: 19) (Baseline: N=94) | eMotion sensor ECG | RHR, ln HF | BM, BMI, BP, HRR | 3 min | Walking | Yes |
| Buchheit et al., | 14 | Polar S810 chest belt | RHR, ln RMSSD (weekly average of 1st and 8th week) | BF, BM, HRR | 5 min | Endurance (continuous runs and intervals) | No |
| Cheema et al., | 37 (TG: 18; CG: 19) | ECG (Sphygmocor) | RHR, ln SDNN, ln RMSSD, pNN50, ln HF, ln LF, ln LF/HF, ln TP | 10 min | Yoga | yes | |
| Chu et al., | 52 (TG: 26, CG: 26) | ECG | LF nu, HF nu, LF/HF | 10 min | Yoga | Yes | |
| Cooke and Carter, | 22 (TG: 12; CG: 10) | 3-lead ECG | mRR, SDNN, LF, HF, LF nu, HF nu | BR, SBP | 5 min | Resistance (whole body) | Yes (recreationally active) |
| da Silva et al., | 30 (HRVG: 15; CG: 15) | Polar RS800CX | RMSSD | HRR | 3 min | Endurance (running) | Yes (predefined training program) |
| Duarte et al., | 40 (TG: 22; CG: 18) | 3-lead ECG | RHR, RMSSD, HF nu, LF nu, LF/HF | HRR | 5 min | Endurance (running) | Yes |
| Gamelin et al., | 10 | Polar S810 | mRR, SDNN, RMSSD, NN50, pNN50, ln (LF+HF), ln LF, ln HF, LF nu, HF nu, LF/HF, SD1, SD2 | VO2 max | 5 min (last 256 s for analysis) | Endurance (intervals and continuous runs on a treadmill) | No |
| Heffernan et al., | 14 | 1-lead ECG | mRR, SDNN, ln TP, ln LF, LF nu, ln HF, HF nu, LF/HF, SampEn, LZEn | BF, BM, HRR, VO2 peak | At least 200 NN intervals | Resistance (whole body) | No |
| Heffernan et al., | 39 | 1-lead ECG | mRR, RMSSD, pNN50, ln TP, ln LF, LF nu, ln HF, HF nu, ln LF/HF, SampEn | BF, BM, BR, HRR, VO2 peak | 15 min (220–260 s for analysis) | Resistance (whole body) | No |
| Heydari et al., | 38 (TG: 20; CG: 18) | Polar RS800CX | RHR, RMSSD, pNN50, ln + ms2 (TP HF, LF, VLF) | BM, BMI, BP, BR, VO2 max | 30 min | HIIE (8 s sprints on cycle ergometer) | Yes |
| Kim et al., | 34 (MAT: 12: HAT: 12; CG: 10) | Polar RS800CX | RHR, RMSSD, pNN50, HF, HF nu, LF nu, LF/HF, SD1, SD1/SD2 | BMI, BP, VO2 max | 10 min | Endurance (walking/running on a treadmill) | Yes |
| Kiviniemi et al., | 53 (ST: 14; HRV-I: 14: HRV-II: 10; CG: 15) | 12-lead ECG | RHR, SD1 | VO2 peak | 5 min | Endurance (running, walking or cycling) | Yes |
| Martinmaki et al., | 11 | Polar Electro | RHR, TP, HF, LF | VO2 peak | 3 × 3 min | Endurance (cycling, running, Nordic Walking) | No |
| McHugh et al., | 16 | 2-lead ECG | HF nu, LF/HF | BF, BM, BMI, HRR, VO2 max | 5 min | Endurance (recreational jogging) | No |
| Moreira et al., | 18 (TG: 10; CG: 8) | Polar RS800CX | RHR, RMSSD, mRR, pNN50, SD1 | BP | 20 min | Capoeira | Yes |
| Nuuttila et al., | 24 (HRVG, 13; PD: 11) | Morning: Garmin 920XT; night: Firstbeat Bodyguard Decvice | RHR, RMSSD, LF, HF, TP | BF, BM, VO2 max | 3 min morning, 4 h night | HIT [running and resistance (whole body)] | No |
| Pal et al., | 60 (20-29y, 30–39y, 40–49y; 20 in each group) | ECG (ProComp) | RHR, mRR, SDNN, RMSSD, pNN50, HF nu, LF nu, LF/HF, TP | BM, BMI, BP | 5 min | Yoga | No |
| de Rezende Barbosa et al., | 29 (FTG: 13; CG: 16) | Polar S810i chest belt | mRR, RRtri, TINN, SD1, SD2, SD1/SD2 | 20 min | Resistance (whole body) | Yes | |
| Schumann et al., | 24 (ST: 14; TLG: 10) | Polar RS800CX | RHR, RMSSD, HF, LF, LF/HF (12th vs. 24th week) | BF, BM, VO2 max (12th vs. 24th week) | 180 s supine, 120 s standing | Endurance (focused on running) | No |
| Sousa Fortes et al., | 31 (CLG: 10; MS: 11; CG: 10) | Polar RS800CX | Ln RMSSD | 5 min | Resistance (bench press and leg press) | Yes | |
| Varela-Sanz et al., | 31 (TT: 11, PT: 10, CG: 10) | Polar S800 | RHR, SDNN, RMSSD, LF, HF | BM, BMI, VO2 max (estimated) | n.r. | 2x endurance (brisk walking or running) and resistance (bench press and half squat), 1x endurance | Yes |
| Wu et al., | 47 (TG: 22; CG: 25; Follow-up: 17) | 1-lead ECG | RHR, SDNN, RMSSD, LF, HF, LF nu, HF nu | BMI | 5 min | Endurance (running on a treadmill) | yes |
AG, age group; BF, body fat; BM, body mass; BMI, body mass index; BP, blood pressure; BR, baroreflex sensitivity; BW, built walk group; CG, control group; CH, control group with high levels of HF at baseline; CL, control group with low levels of HF at baseline; CLG, clustering group; ECG, electrocardiography; FTG, functional training group; HAT, high-intensity aerobic training; HF (nu), power in high frequency range (in normalized units); HIIE, high-intensity intermittent exercise; HRR, heart rate recovery; HRV-I and II, HRV guided training based on daily HRV measurements; HRVG, HRV guided training group; IHG3, isometric handgrip training 3 days per week; IHG5, isometric handgrip training 5 days per week; LF (nu), power in low frequency range (in normalized units); ln, natural logarithm; LZEn, Lempel-Ziv entropy; MAT, moderate-intensity aerobic training; MS, multi-sets group; mRR, mean RR interval; NN50, number of pairs of adjacent NN intervals differing by more than 50 ms in the entire recording; n.r., not reported; NW, nature walk group; PD, predetermined training group; pNN50, NN50 count divided by the total number of all NN intervals; PT, polarized training group; RHR, resting heart rate; RMSSD, square root of the mean of the sum of the squares of differences between adjacent NN intervals; RRtri, HRV triangular index; SampEn, sample entropy; SBP, systolic blood pressure; SD1, standard deviation of instantaneous beat-to-beat variability, extracted from Poincaré Plot; SD2, standard deviation of the long-term variability, extracted from Poincaré Plot; SDNN, standard deviation of NN intervals; ST, standard training group; TG, training group; TH, training group with high levels of HF at baseline; TINN, baseline width of the minimum square difference triangular interpolation of the highest peak of the histogram of all NN intervals; TL, training group with low levels of HF at baseline; TLG, training load-guided (based on estimated cumulated training load); TP, total power; TT, traditional-based group; VLF, power in very low frequency range; VO.
Outcome of HRV measures, cardiovascular and health risk factors, TESTEX, and STARDHRV score.
| Badrov et al., | Within | After 4 weeks: IHG3: ↑ RHR, SDNN, RMSSD, and HF nu; ↓ pNN50, ln LF, LF nu, LF/HF, and α1; ↔ ln HF, SampEn, and TP; IHG5: ↑ SDNN, RMSSD, pNN50, ln LF, ln HF, LF nu, TP, and SampEn; ↓ RHR, HF nu, LF/HF, and α1. After 8 weeks (compared to baseline): IHG3: ↑ SDNN, RMSSD, pNN50, and HF nu; ↓ RHR, ln LF, LF nu, and LF/HF; IHG5; ↔ ln HF, TP, SampEn, and α1; IHG5: ↑ SDNN, RMSSD, ln HF, HF nu, and SampEn; ↓ pNN50, ln LF, LF nu, TP, and LF/HF; ↔ RHR and α1. | Both groups: after 4 weeks: ↓ SBP (IHG3 | 12.5 | 22 |
| Bond et al., | Within | ↑ HF nu; ↓ RHR | ↑ VO2 peak | 9 | 19 |
| Boutcher et al., | Within | ↓ RHR and LF nu; ↑ HF (ms2, nu, ln | ↑ VO2 max | 6.5 | 15.5 |
| Brown et al., | Within | ↓ ln HF (NW and BW); ↑ RHR (NW and BW) | ↑ SBP (BW); ↓ SBP | 10 | 17.5 |
| Buchheit et al., | Within | ↑ln RMSSD | ↓ BF, BM, and HRR | 4 | 17.5 |
| Cheema et al., | Between | ↑ ln LF/HF | 9.5 | 18.5 | |
| Chu et al., | Within | ↑ LF nu and LF/HF; ↓ HF nu | 13 | 21.5 | |
| Cooke and Carter, | Within | ↑ SDNN, LF, LF nu, HF, and HF nu; ↓ mRR | ↑ BR; ↓ SBP (elsewhere published) | 9 | 20 |
| da Silva et al., | Within | Both groups: ↑ RMSSD (HRVG | Both groups: ↑ HRR (HRVG | 12.5 | 20 |
| Duarte et al., | Within | ↑ RMSSD in TL | Both groups: ↑ HRR | 11 | 23 |
| Gamelin et al., | Within | ↑ SDNN, RMSSD, NN50, pNN50, ln (LF+HF) | ↑ VO2 max | 4 | 18 |
| Heffernan et al., | Within | ↑ SDNN, ln LF, LF nu, ln HF, LF/HF, SampEn | ↑ BF, BM, HRR | 4.5 | 21.5 |
| Heffernan et al., | Within | African Americans: ↑ RMSSD, pNN50, ln TP, ln HF, HF nu, and SampEn | African Americans: ↑ BM | 4.5 | 21.5 |
| Heydari et al., | Between | ↑ TP, ln TP, VLF, ln VLF, LF, ln LF | ↑ BR | 9 | 17.5 |
| Kim et al., | Between | MAT: ↑ RMSSD, pNN50, HF, HF nu, SD1 and SD1/SD2; ↓ RHR, LF/HF and LF nu. HAT: ↑ RMSSD | MAT and HAT: ↑ VO2 max (HAT | 5.5 | 16.5 |
| Kiviniemi et al., | Within | ↑ SD1 (ST in women, HRV-I in men | All groups: ↑ VO2 peak | 4.5 | 15.5 |
| Martinmaki et al., | Within | Supine: ↑ ln HF and ln TP; ↔ RHR and ln LF. Sitting: ↑ ln HF, ln LF, and ln TP; ↓ RHR | ↑ VO2 peak | 6.5 | 20 |
| McHugh et al., | Within | ↑ LF/HF; ↓ HF nu | ↑VO2 max, HRR (2nd minute after test) | 3.5 | 20.5 |
| Moreira et al., | Within | ↑ mRR | ↓ DBP | 10 | 16.5 |
| Nuuttila et al., | Within | Nocturnal: both groups: ↑ RMSSD (HRVG | both groups: ↑ VO2 max | 10 | 16.5 |
| Pal et al., | Within | All groups: ↑ HF nu (AG I | All groups: ↓ DBP (AG III) and SBP (AG II and AG III | 6.5 | 18 |
| de Rezende Barbosa et al., | Between | ↑ RRtri | 6 | 19.5 | |
| Schumann et al., | Within | ST: supine: ↑ LF; ↓RMSSD, HF and LF/HF; ↔ RHR; stand: ↑ LF and LF/HF; ↓ RHR, RMSSD, and HF (correct value?). TLG: supine: ↑ RMSSD, HF, and LF/HF; ↓ RHR and LF; stand: ↑ RMSSD, HF, and LF/HF; ↓ RHR andLF | ST: ↑ VO2 max | 7.5 | 16 |
| Sousa Fortes et al., | Between and within | CLG and MS: ↑ ln RMSSD | 10 | 16.5 | |
| Varela-Sanz et al., | Within | TT: supine: ↑ SDNN, RMSSD, LF, and HF; ↓ RHR | Both groups: ↑ BM (PT | 10.5 | 16 |
| Wu et al., | Within | ↑ RHR, HF, and HF nu; ↓ SDNN, RMSSD, and LF | ↓ BMI | 6 | 15 |
AG, age group; BF, body fat; BM, body mass; BMI, body mass index; BR, baroreflex sensitivity; BR down-down, BR during hypotensive changes in systolic blood pressure; BR up-up, BR during hypertensive changes in systolic blood pressure; BW, built walk group; CG, control group; CLG, clustering group; DBP, diastolic blood pressure; HAT, high-intensity aerobic training; HF (nu), power in high frequency range (in normalized units); HRR, heart rate recovery; HRV-I and II, HRV guided training based on daily HRV measurements; HRVG, HRV guided training group; IHG3, isometric handgrip training 3 days per week; IHG5, isometric handgrip training 5 days per week; LF (nu), power in low frequency range (in normalized units); ln, natural logarithm; LZEn, Lempel-Ziv entropy; MAT, moderate-intensity aerobic training; MS, multi-sets group; mRR, mean RR interval; NN50, number of pairs of adjacent NN intervals differing by more than 50 ms in the entire recording; NW, nature walk group; PD, predetermined training group; pNN50, NN50 count divided by the total number of all NN intervals; PT, polarized training group; RHR, resting heart rate; RMSSD, square root of the mean of the sum of the squares of differences between adjacent NN intervals; RRtri, HRV triangular index; SampEn, sample entropy; SBP, systolic blood pressure; SD1, standard deviation of instantaneous beat-to-beat variability, extracted from Poincaré Plot; SD2, standard deviation of the long-term variability, extracted from Poincaré Plot; SDNN, standard deviation of NN intervals; ST, standard training group; TH, training group with high levels of HF at baseline; TINN, baseline width of the minimum square difference triangular interpolation of the highest peak of the histogram of all NN intervals; TL, training group with low levels of HF at baseline; TLG, training load-guided (based on estimated cumulated training load); TP, total power; TT, traditional-based group; VLF, power in very low frequency range; VO.
significant difference (pre vs. post or trainings vs. control group); ↑, increase; ↓, decrease.